IV Vidaza Approved; Oral Formulation to Be Tested

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

IV Vidaza Approved; Oral Formulation to Be Tested

BOULDER, Colorado—The FDA has approved Pharmion Corporation's NDA supplement to add IV use as a new route of administration for the company's DNA demethylation agent Vidaza (azacitidine) for the treatment of myelodysplastic syndrome (MDS). Hypomethylation may restore normal function to genes critical for differentiation and proliferation. A parenteral formulation of the agent is currently available.

The company also received an IND for the first human trial of oral Vidaza. The phase I trial will include patients with MDS, acute myelogenous leukemia, and malignant solid tumors.

Articles in this issue
Peptide-Based Breast Ca Vaccines Promising in Early Trials
Diagnostic Dilemma: GI Disease
Imatinib Responses in CML May Take Time
IV Vidaza Approved; Oral Formulation to Be Tested
Study Confirms Avastin Advantage in Advanced NSCLC
Legal Services Should Be a Component of Standard Cancer Care
Mouse Virus Evidence Suggests Viral Basis for Breast Ca
Groups Oppose Ruling on Access to Experimental Drugs
Satellite Allows Digital Mammography Screening for Rural Native Americans
Nexavar Effective in Advanced HCC: Phase III Trial Stopped
H&N Ca Patients With CR to CRT May Not Need Surgery
Two Sets of Researchers Find Herceptin Cost Effective
Family-Based Testing Strategy May Better Detect HNPCC
More 'Promacs,' Worse Outcome
Brachytherapy Balloon Can Be Placed After Final Pathology
Recent Videos
Related Content
The guideline update follows the FDA’s approval of imetelstat in patients with lower-risk MDS based on data from the phase 3 IMerge trial.

Updated NCCN Guidelines Recommend Imetelstat for Anemia in Lower-Risk MDS

Roman Fabbricatore
July 31st 2024
Article

The guideline update follows the FDA’s approval of imetelstat in patients with lower-risk MDS based on data from the phase 3 IMerge trial.

Safety Profile of Oral Azacitadine Remains Consistent in Lower-Risk MDS

Safety Profile of Oral Azacitadine Remains Consistent in Lower-Risk MDS

Ashley Chan
June 2nd 2024
Article

The safety profile of oral azacitadine was shown to be similar across the 200-mg and 300-mg arms in patients with lower- to intermediate-risk MDS.

Data from the phase 3 COMMANDS trial support the expanded European approval of frontline luspatercept for transfusion-dependent anemia in lower-risk myelodysplastic syndromes.

Luspatercept Earns Expanded European Approval for Anemia in Lower-Risk MDS

Russ Conroy
April 3rd 2024
Article

Data from the phase 3 COMMANDS trial support the expanded European approval of frontline luspatercept for transfusion-dependent anemia in lower-risk myelodysplastic syndromes.

Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.

FDA ODAC Votes in Favor of Imetelstat Benefits Vs Risks in Lower-Risk MDS

Russ Conroy
March 14th 2024
Article

Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.

Treatment with rusfertide may reduce the use of phlebotomy and limit debilitating disease-related symptoms in patients with polycythemia vera based on findings from the phase 2 REVIVE trial.

Rusfertide May Help Control Erythrocytosis in Polycythemia Vera

Russ Conroy
March 8th 2024
Article

Treatment with rusfertide may reduce the use of phlebotomy and limit debilitating disease-related symptoms in patients with polycythemia vera based on findings from the phase 2 REVIVE trial.

Treatment with imetelstat produces robust activity in patients with relapsed/refractory myelodysplastic syndrome regardless of ring sideroblasts in the phase 3 IMerge trial.

Imetelstat Yields Enduring RBC-TI in Lower-Risk Relapsed/Refractory MDS

Russ Conroy
January 16th 2024
Article

Treatment with imetelstat produces robust activity in patients with relapsed/refractory myelodysplastic syndrome regardless of ring sideroblasts in the phase 3 IMerge trial.